Indications for JORNAY PM:
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. Swallow whole or may open caps and sprinkle contents onto applesauce; do not chew beads. Give only in the PM; avoid AM dose. Take at same time every day. Individualize. ≥6yrs: initially 20mg once daily at 8PM (may adjust between 6:30PM–9:30PM). May titrate in 20mg increments weekly; daily dose >100mg: not recommended. Discontinue if no improvement seen after 1 month. Switching from other methylphenidate products: discontinue and follow Jornay PM titration schedule. Not interchangeable on a mg-per-mg basis.
During or within 14 days of MAOIs.
Abuse and dependence.
High potential for abuse and dependence; monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors of developing a manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
See Contraindications. Hypertensive crisis with MAOIs.
Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, BP increased; priapism, hypersensitivity, cardiovascular reactions. Children also: headache, psychomotor hyperactivity, mood swings.
Register pregnant patients in the National Pregnancy Registry for Psychostimulants by calling (866) 961-2388.